New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
about
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome.Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome.
P2860
New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
New therapeutic options for IB ...... agonist (mudelta) eluxadoline.
@en
New therapeutic options for IB ...... d δ-opioid receptor antagonist
@nl
type
label
New therapeutic options for IB ...... agonist (mudelta) eluxadoline.
@en
New therapeutic options for IB ...... d δ-opioid receptor antagonist
@nl
prefLabel
New therapeutic options for IB ...... agonist (mudelta) eluxadoline.
@en
New therapeutic options for IB ...... d δ-opioid receptor antagonist
@nl
P2860
P1476
New therapeutic options for IB ...... agonist (mudelta) eluxadoline.
@en
P2860
P304
P356
10.1080/17474124.2017.1298442
P577
2017-03-01T00:00:00Z